Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Key Sessions

Oliver Thiel, Ph.D.

CASE STUDY: Expressed Protein Ligation as Bioconjugation Platform


8 am 8:15 am (15 mins)

Opening Remarks

8:15 am 8:45 am (30 mins)

CASE STUDY: Expressed Protein Ligation as Bioconjugation Platform

In this session Dr. Thiel will discuss how expressed protein ligation offers a practical solution to conjugate peptides on the C-terminus of proteins.

  • Oliver Thiel, Ph.D., Director Process Development, Amgen

8:45 am 9:15 am (30 mins)

NEW DATA: Cysteine Arylation for Site-Specific Antibody Conjugation

Here we report a robust bioconjugation method using cysteine arylation. This chemistry enables site-specific conjugation at cysteine residues within peptides, proteins, and antibodies. Our two developed approaches use either perfluoroaryl-cysteine SNAr chemistry or organometallic palladium reagents. Recently, we discovered a self-labeling four-residue sequence that enables regioselective conjugation at only one cysteine residue within an intact antibody containing natural amino acids.

  • Bradley L. Pentelute, Ph.D., Career Development Professor; Associate Member, Broad Institute of Harvard and MIT; Member, Center for Environmental Health Sciences MIT, Pfizer-Laubach

9:15 am 9:45 am (30 mins)

Creating Next Generations ADCs with Unnatural Amino Acids (uAAs)

Amino acids with non-natural side chains can be genetically encoded into proteins and used for site specific modification. We have created next-generation antibody conjugates by directly coupling drugs, as well as nucleic acids to unnatural amino acids on antibodies. This basic technology lends itself to creation of not only drug conjugates, but also novel multimeric structures through nucleotide basepairing.

  • Vaughn Smider, Chief Scientific Officer; Asst Professor, The Scripps Research Institute, Sevion Therapeutics

9:45 am 10:15 am (30 mins)

Networking Refreshment Break in Poster & Exhibit Hall

10:15 am 10:45 am (30 mins)

NEW DATA: Site Specific Conjugation through Antibody Glycans with PBD Dimers

  • Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH

10:45 am 11:15 am (30 mins)

NEW DATA: Metal-Mediated Site-Selective Labeling of Wild-Type Proteins

  • Michael Rosholm Mortensen, Ph.D. Student, Chemistry and iNANO, Aarhus University

11:15 am 11:45 am (30 mins)

CASE STUDY: Selection of Cell Binding and Internalizing Phage Abs for Targeted Drug Delivery

hage antibody technology has been typically applied to the generation of antibodies to purified proteins, it is also possible to directly select cell binding and internalizing antibodies on cells. This allows use of the antibody to deliver a range of payloads into the cell to achieve a therapeutic effect.

  • Yu Zhou , Associate Adjunct Professor, Department of Anesthesia, University of California, San Francisco

11:45 am 12:15 pm (30 mins)

Technology Workshop - Enzymatic Ligation as a Tool for Assembling Bioconjugates

Sponsored by EnzyPep

  • Rodney Lax, Ph.D., Scientific Advisor & Business Development Consultant, EnzyPep B.V.

12:15 pm 1:25 pm (70 mins)

Networking Luncheon in the Poster & Exhibit Hall

1:25 pm 1:55 pm (30 mins)

Staphylococcus Aureus Vaccine Development

  • Ingrid Scully, Vaccine Research and Development, Pfizer, Inc.

1:55 pm 2:25 pm (30 mins)

NEW DATA: Targeted Protein Therapeutics (TPTs) for the Systemic and Local-regional Treatment of Cancer

TPTs incorporate antibody fragments and protein toxin payloads into a single gene-fused molecule. Results will be presented from phase II clinical trials in non-muscle invasive bladder cancer and squamous cell carcinoma of the head and neck with TPTs targeting Ep-CAM. Clinical evidence of successful de-immunization of our deBouganin payload TPTs and their lack of sensitivity to multidrug resistance mechanisms will also be presented.

  • Greg Adams, Ph.D., Chief Development Officer, Viventia Biotechnologies Inc

2:25 pm 3 pm (35 mins)

Immune Checkpoint Inhibitors – Combinatorial Approaches in Melanoma and Other Malignancies

While PD-1 pathway blockade has remarkable single agent activity in subsets of patients, the combinationof PD-1 and CTLA-4 inhibition increases the efficacy (and toxicity) of PD-1 inhbition in melanoma, leadingto FDA approval of the combination of nivolumab and ipilimumab. Building on the experience in melanoma,multiple variables contributing to successful immune checkpoint combination strategy, including dosing andscheduling will be presented. Key principles governing rational immunooncology combination strategies willbe highlighted.

  • Patrick A. Ott, MD, Ph.D.,, Clinical Director, Melanoma Disease Center and Center for Immuno-Oncology, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute

3 pm 3:30 pm (30 mins)

Networking Refreshment Break in Poster & Exhibit Hall

3:30 pm 4:15 pm (45 mins)

Adoptive T Cell Therapy and Immune Checkpoint Inhibitors: A Combination Strategy for Cancer Treatment

Adoptive cellular therapy can provide large numbers of tumor-reactive T cells especially in cases where the endogenous T cell response is inadequate. Combining the use of ACT with Immune Checkpoint Inhibitors can lead to a synergistic response in patients with solid tumor malignancies. Judicious use of combination approaches may be facilitated through the use of a well-defined population of adoptively transferred T cells as a transferrable cellular biomarker.

  • Cassian Yee, MD, Professor, Department of Immunology, MD Anderson Cancer Center

4:15 pm 5 pm (45 mins)

NEW DATA: Development of a Vaccine to Interrupt Malaria Transmission using a Chemically Conjugated Protein-protein nanoparticle platform

One approach to develop an effective malaria vaccine is to produce a well-characterized recombinant protein based, chemical conjugate vaccine that interferes with malaria transmission in humans and the mosquito host. The vaccine would be comprised of a blend of a carrier conjugated to recombinant malarial proteins which form nanoparticles that significantly enhance immunogenicity. In phase 1 trials, conjugate vaccines targeting mosquito transmission appear to be safe and induce functional antibodies that human complement may enhance.

  • David L. Narum, Ph.D., Head, Process Development Unit, Laboratory of Malaria Immunology and Vaccinology, NIH

5 pm 7 pm (120 mins)

Networking Cocktail Reception in the Poster & Exhibit Hall